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Abstract
Colorectal cancer (CRC) remains a leading cause of cancer mortality. Here, we define the colonic epithelial expres-
sion of cathelicidin (LL-37) in CRC. Cathelicidin exerts pleotropic effects including anti-microbial and immunoregu-
latory functions. Genetic knockout of cathelicidin led to increased size and number of colorectal tumours in the
azoxymethane-induced murine model of CRC. We aimed to translate this to human disease. The expression of LL-
37 in a large (n = 650) fully characterised cohort of treatment-naïve primary human colorectal tumours and
50 matched normal mucosa samples with associated clinical and pathological data (patient age, gender, tumour
site, tumour stage [UICC], presence or absence of extra-mural vascular invasion, tumour differentiation, mismatch
repair protein status, and survival to 18 years) was assessed by immunohistochemistry. The biological consequences
of LL-37 expression on the epithelial barrier and immune cell phenotype were assessed using targeted quantitative
PCR gene expression of epithelial permeability (CLDN2, CLDN4, OCLN, CDH1, and TJP1) and cytokine (IL-1β, IL-18,
IL-33, IL-10, IL-22, and IL-27) genes in a human colon organoid model, and CD3+, CD4+, and CD8+ lymphocyte
phenotyping by immunohistochemistry, respectively. Our data reveal that loss of cathelicidin is associated with
human CRC progression, with a switch in expression intensity an early feature of CRC. LL-37 expression intensity is
associated with CD8+ T cell infiltrate, influenced by tumour characteristics including mismatch repair protein sta-
tus. There was no effect on epithelial barrier gene expression. These data offer novel insights into the contribution
of LL-37 to the pathogenesis of CRC and as a therapeutic molecule.
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Introduction
Human cathelicidin (and its bioactive derivative LL-37)
is an anti-microbial peptide, expressed by epithelial cells
at mucosal surfaces and a wide array of immune cells
[1]. LL-37 is anti-microbial, acts as a chemoattractant,
impacts innate and adaptive immune cell responses, con-
tributes to host–microbiome interaction, and has a role
in wound healing [2,3]. Cathelicidin plays a role in the
pathogenesis of malignancy and, given its pleotropic
biological responses, can exert pro-malignant or anti-
tumoural effects and this is dependent on tissue type
© 2021 The Authors. The Journal of Pathology: Clinical Research published by The Pathological Society of Great Britain and Ireland & John Wiley &
Sons, Ltd.
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[2,4]. In the gut, genetic knockout of cathelicidin
(CRAMP in the mouse) led to shorter crypt length
implying a homeostatic role in colonic epithelial growth
dynamics [5]. Presence of cathelicidin is associated with
a robust mucus layer in structure and function [6,7].
There is evidence to suggest a protective role of cat-
helicidin in colonic carcinogenesis through effects on
growth dynamics, particularly apoptosis and autophagy,
angiogenesis, and fibroblast activity [1,2,8] and linked to
the colonic microbiome [5]. Our previous data revealed
that genetic knockout of CRAMP (murine cathelicidin)
led to increased tumour size and number in the
azoxymethane-induced murine model of colorectal can-
cer (CRC), suggesting a tumour-suppressive role [5].
CRC remains a leading cause of cancer in the UK and
worldwide [9]. Despite advances in treatments and earlier
detection through national screening programmes, many
people still die from this malignancy. CRC is ranked as the
second most lethal cancer, accounting for 9.2% of cancer
mortality [9]. Therefore, there is a clinical need to increase
understanding of the pathogenesis of this malignancy and
to develop prognostic biomarkers and new treatment
targets.
The pathogenesis of CRC is multifactorial and
involves a series of genetic and epigenetic mutations,
microbial dysbiosis, intestinal inflammation, and epi-
thelial barrier dysfunction [10–12].
The key question now is whether the protective role
for LL-37 in our pre-clinical studies translates to
human disease. Evidence for this is limited. Ren et al
[13] characterised cathelicidin expression in a cohort
of 102 human CRCs and demonstrated a reduced
expression compared to normal colon tissue.
This study aimed to define the epithelial cytoplasmic
expression profile of cathelicidin linked to clinico-
pathological factors in human CRC, assess whether
this could be a biomarker for prognosis, and explore the
biological consequences of expression on the epithelial
barrier and immune cell phenotype.
We now demonstrate the expression of LL-37 in a
large (n = 650) fully characterised cohort of treatment-
naïve primary human colorectal tumours and 50 mat-
ched normal mucosa samples and show expression
intensity of epithelial cathelicidin is associated with
human CRC progression and CD8+ T cell infiltrate.
Materials and methods
Ethical approval
Ethical approval for use of human tissue and data in
this study was obtained from the Scientific Access
Committee of the Grampian Tissue Biorepository
(Tissue Request No. 000135 for Tissue Microarray
and 000176 for organoid culture). The biorepository
has delegated research ethics authority (11/NS/0015)
from The North of Scotland Research Ethics Commit-
tee to approve research projects involving human tis-
sue and data. All tissue and data were anonymised.
Project specific written consent was not required for
the retrospective use of archival tissue. Patients pro-
vided written consent prior to surgery for the use of
their resected tissue for research purposes to the
Grampian Tissue Biorepository and this was subse-
quently used for the organoid culture model.
Colorectal cancer tissue microarray
Formalin-fixed paraffin-embedded tissue cores from
650 CRCs and 50 matched normal pairs were presented
within a previously published well-characterised tissue
microarray (TMA) with long-term overall survival
data [14–16]. Tissue cores were obtained from chemo-
therapy and radiotherapy-naïve patients undergoing
elective surgery for primary CRC between 1994 and
2009 at Aberdeen Royal Infirmary, Scotland, UK. Each
tumour was histologically reported according to the
Royal Collage of Pathologists UK guidelines, and rep-
resented by two 1 mm cores on the tissue microarray.
The area of the tumour to be sampled for microarray
construction was selected by an expert gastrointestinal
pathologist (GIM) based on histological assessment of
a formalin-fixed paraffin-embedded section of the
tumour. The normal mucosal samples were retrieved
from the resection margin, from an area at least 10 cm
distant from the tumour. The relationship between
clinico-pathological parameters and overall survival
validates the tissue microarray as representative of
pathology (Table 1).
Clinical and pathological data
Clinical and pathological data were available for each
case represented on the tissue microarray as described
in Table 1. Clinical data included survival up to
18.2 years (mean 5.5 years, SD 3.8), patient age at re-
section and gender, alongside tumour characteristics
such as tumour site and stage [The Union for Interna-
tional Cancer Control (UICC)] as a composite score
from tumour stage and nodal status). Pathological data
included presence or absence of extra-mural vascular
invasion (EMVI), tumour differentiation, and mis-
match repair protein status defined by proficient
or deficient MLH1 and MSH2 status determined by
immunohistochemistry.
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Immunohistochemistry
Intensity of epithelial cytoplasmic LL-37 was assessed
by immunohistochemistry using rabbit anti-human cat-
helicidin antibody (ab69484; Abcam, Cambridge, UK) at
a dilution of 1:200. Tissue sections of 4 μm were cut and
placed onto 3-aminopropyltriethoxysilane-coated slides for
immunohistochemical analysis. Specimens were dewaxed
in xylene and rehydrated in alcohol. Antigen retrieval was
performed in EDTA (pH 7.8) buffer for 20 min. EnVision
+™ peroxidase-linked, biotin-free synthesis (Dako, Ely,
UK) with 3’-3’-diaminobenzidine as chromogen was used
for detection using a Dako Autostainer (Dako), as previ-
ously published [14–17]. Sections were counterstained
with haematoxylin. Primary antibody was applied to the
tissue sections and incubated for 60 min within the
staining protocol. A negative (omitting primary antibody)
and positive control (human spleen) were included.
The immunohistochemical assessment of lympho-
cyte infiltrate (CD3+, CD4+, and CD8+ cells) was
performed as part of a different study as previously
published [18], and the raw data were obtained
through the Grampian Biorepository for this new anal-
ysis. In summary, CD3+ and CD4+ cells were
detected using the Ventana Benchmark XT autostainer
(Ventana Medical Systems, Oro Valley, AZ, USA),
whereas CD8 was detected using the Leica autostainer
(Leica Biosystems, Wetzlar, Germany) [18]. The
immunostaining was completed using CONFIRM
Anti-CD3 (clone: 2GV6) and CONFIRM anti-CD4
(clone: SP35) neat primary rabbit monoclonal anti-
bodies (Ventana Medical Systems), and anti-CD8
(clone: CD/144B) primary mouse antibody at a dilu-
tion of 1:50 (Agilent Technologies, Santa Clara, CA,
USA). Antigen retrieval was performed using Cell
Table 1. CRC tissue microarray with clinico-pathological data.
Characteristic No. of patients Percentage Relationship with survival
Gender
Male 340 52.3 χ2 = 0.027, p = 0.870
Female 310 47.7
Age
<70 305 46.9 χ2 = 29.213, p < 0.001
≥70 345 53.1
Screening detected
Yes 52 8 χ2 = 16.381, p < 0.001
No 598 92
Tumour site
Proximal colon 261 40.2 Proximal versus distal, χ2 = 8.418, p = 0.004
Distal colon 245 37.7 Distal versus rectal, χ2 = 0.906, p = 0.341
Rectum 144 22.2 Colon versus rectum, χ2 = 0.098, p = 0.754
Tumour differentiation
Well/moderate 600 92.3 χ2 = 0.976, p = 0.323
Poor 50 7.7
Extra-mural venous invasion (EMVI)
Present 140 21.5 χ2 = 100.946, p < 0.001
Absent 510 78.5
Mismatch repair protein status (defined by MLH1 and MSH2 immunohistochemistry)
Deficient 96 15.2 χ2 = 2.848, p = 0.091
Proficient 536 84.8
pT stage
T1 30 4.6 T1 versus T2, χ2 = 0.382, p = 0.536
T2 114 17.5 T2 versus T3, χ2 = 24.739, p < 0.001
T3 411 63.2 T3 versus T4, χ2 = 30.159, p < 0.001
T4 95 14.6
pN stage
N0 364 56 N0 versus N1, χ2 = 54.071, p < 0.001
N1 177 27.2 N1 versus N2, χ2 = 17.636, p < 0.001
N2 109 16.8
The Union for International Cancer Control (UICC) stage
1 120 18.5 A versus B, χ2 = 5.059, p = 0.025
2 244 37.5 B versus C, χ2 = 65.510, p < 0.001
3 286 44
Analysis with chi-square tests validates the TMA as representative of pathology. Values in bold indicate p < 0.05.
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Conditioning Solution (CC1) buffer (Ventana Medical
Systems) for 32 and 60 min for anti-CD3 and anti-
CD4, respectively. Antigen retrieval for anti-CD8 was
completed using ER2 solution (Leica Biosystems) for
20 min. Primary antibodies were applied for 16 min at
37C for anti-CD3 and anti-CD4, and 15 min at room
temperature for anti-CD8 [18]. A negative (omitting
primary antibody) and positive control (human tonsil)
were included.
Scoring of LL-37 expression
Expression intensity of epithelial cytoplasmic LL-37
was independently assessed by two observers (RJP
and MHM), blinded to clinical and pathological data,
as absent, weak, moderate, or strong by light micros-
copy as previously published [14–17]. LL-37 expres-
sion was heterogeneous across the cores and therefore
we applied the criteria of reporting on the area of most
positive expression intensity and this was applied to
all cores to ensure uniformity of approach. Any dis-
crepancies in the scores were resolved through simul-
taneous re-evaluation of the cores by both observers,
and review by an expert gastrointestinal pathologist
(GIM). Cases were recorded as missing if the evalua-
tion of immunostaining was not possible due to the tis-
sue cores being damaged/folded during the tissue
preparation process or there were no tumour cells pre-
sent in the core.
Scoring of immune cell phenotype
All slides immunostained for immune cell infiltrate
were scanned at 40 magnification using a Leica
Aperio AT2 whole slide scanner and digital image
analysis conducted as previously published [18]. In
brief, immunostaining of all immune cell biomarkers
was scored using QuPath software version 0.1.2 [19].
The cores were first annotated with the assistance of a
senior consultant pathologist before applying an auto-
mated scoring algorithm for each immune biomarker
[18]. Cases were recorded as missing if the evaluation
of immunostaining was not possible due to the tissue
cores being damaged or folded. Immune cell results
were quantified according to average density of posi-
tive cells present for all TMA cores available for each
patient. These results were then ranked by increasing
density and four equal groups representing increasing
relative immune cell density within the patient cohort
were generated in order to create immune phenotype
data comparable to the data generated for LL-37
expression groups.
Human colon-derived epithelial organoid model
A human colon-derived epithelial organoid model was
established from fresh colon tissue, optimised at our
centre from a previously published protocol [20]. A
3–5-cm3 piece of non-neoplastic colonic mucosa, dis-
sected from the resection margin, was washed in cold
DPBS, cut into 5–10 mm pieces, and chelated in
2.5 mM EDTA buffer on ice for 40 min with gentle
agitation. Tissue was shaken vigorously to liberate
crypts and passed through a 100-μm cell strainer.
Crypt containing elute was centrifuged at 4 C at
300  g for 3 min and the pellet was resuspended in
cold DPBS and washed three times to remove single-
cell debris. Crypts were suspended in Matrigel©
(Corning, NY, USA), supplemented with 1:100 Jag-
ged-1-peptide, at 200 crypts/15 μl Matrigel©. Crypt-
Matrigel© mixture/well of 15 μl was dispensed into a
pre-warmed delta-surface 24-well plate, and Matrigel©
polymerised by inverting plate at 37C for 15 min. For
initiating, maintaining, and differentiation of colonic
organoid culture, a 50% conditioned media (1:1 dilu-
tion in advanced DMEM/F12 base media) was used,
generated from genetically modified L-WRN mouse
fibroblast cell line (CLR-3276; ATCC, Manassas, VA,
USA) cultured in advanced D-MEM/F12 with 10%
FCS, 0.5 mg/ml hygromycin-B, and 0.5 mg/ml G-418.
This cell line secretes human Wnt3A, R-spondin, and
noggin, essential factors for intestinal epithelial cell
organoid culture. Additional components of the initiation
media are listed in Supplementary materials and
methods. Organoids were cultured at 37 C in 5% CO2.
After 48 h, initiation media was replaced with mainte-
nance media (see Supplementary materials and methods)
and this was replaced every 3–4 days. Before experimen-
tal stimulations, organoids were plated on delta-surface
96-well plates and cultured in fully recombinant differen-
tiation media (see Supplementary materials and methods)
for at least 3–4 days to maturity.
Epithelial permeability and cytokine gene
expression profile
RNA was extracted from organoid cultures (n = 3 indi-
vidual patients with 3 technical replicates/experiment)
using RNeasy RNA isolation kit (Qiagen, Hilden, Ger-
many) and quantified by Nanodrop spectroscopy. RT-
qPCR using TaqMan assays (Applied Biosystems, Foster
City, CA, USA) characterised organoid permeability
(CLDN2, CLDN4, OCLN, CDH1, and TJP1) and
epithelial-derived cytokine (IL-1β, IL-18, IL-33, IL-10,
IL-22, and IL-27) gene expression normalised to GAPDH
and B2M following a 48-h stimulation with recombinant
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LL-37 (TOCRIS 154947-66-7, Tocris Bioscience,
Avonmouth, UK) at 0 and 100 ng/ml. Relative gene
expression was calculated using the Livak method [21].
Data analysis
Data were analysed with IBM®SPSS® Version 25.0
(IBM, Portsmouth, UK) and Prism Version 8 (Gra-
phPad Software Inc., San Diego, CA, USA). Statistical
tests were Pearson’s chi-square test, Fisher’s exact test,
ANOVA, and log-rank test with Kaplan–Meier sur-
vival analysis, as appropriate. A two-tailed alpha was
set at 0.05 and 95% CIs were included where appro-
priate. Scores for LL-37 expression were also
dichotomised using negative versus positive staining,
negative and weak staining versus moderate and strong
staining, and strong versus negative/weak/ moderate
staining comparisons as previously published [14–17].
For survival analysis and for comparison with LL-37,
the scores of immune cell biomarkers were
(1) dichotomised based on quartiles into four different
categories (0, 1, 2, and 3 representing 0–25, 26–50,
51–75, and 76–100% density as a percentage of total
immune cell density, respectively) and (2) assessed as
continuous data defined as the number of immune
cells per core. All analyses were performed without
imputation of missing values.
Results
Representative photomicrographs of epithelial cytoplas-
mic LL-37 expression intensity across colorectal neoplas-
tic progression are shown in Figure 1. In terms of
interobserver variability of LL-37 expression intensity,
considering full assessment of cores (1 [no epithelial
component], 0 [absent], 1 [weak], 2 [moderate], and
Figure 1. Representative photomicrographs of epithelial cytoplasmic LL-37 expression intensity in (A) normal colonic mucosa, (B) UICC
stage 1 CRC, (C) UICC stage 2 CRC, and (D) UICC stage 3 CRC. The digital photographs were taken using an Olympus BX51 microscope
with a digital Olympus camera (Olympus, Tokyo, Japan), with objective magnification of 20.
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3 [strong]), Cohen’s kappa was 0.848 (95% CI 0.824,
0.872; p < 0.001). When considering scores that either
assessor scored 0, 1, 2, and 3, the weighted kappa was
0.865 (95% CI 0.842, 0.887; p < 0.001). In both scenar-
ios, a score of 0.81–1.00 indicates a satisfactory agree-
ment between observers.
Figure 2. Frequency analysis of epithelial cytoplasmic LL-37 expression intensity in normal and CRC tissue. (A) CRC tissue has reduced
expression intensity of LL-37 compared with normal tissue. (B) Loss of LL-37 expression intensity occurs during the early stages of colo-
rectal carcinogenesis. (C) Differential epithelial cytoplasmic LL-37 expression intensity in non-neoplastic colorectal epithelium adjacent
to CRCs of different stage.
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Loss of LL-37 expression in colonic epithelial cells
is associated with CRC
All non-neoplastic normal tissue expressed LL-37 in
the cytoplasm of epithelial cells, with 30% (13/44),
34% (15/44), and 36% (16/44) expressing weak, mod-
erate, and strong intensity, respectively. Expression
intensity of LL-37 was significantly reduced in CRC
(absent versus weak versus moderate versus strong
expression intensity, p < 0.001) (Figure 2A and
Table 2, row 1). Of 589 CRC cores, 63 (11%) did not
express LL-37. Of those expressing epithelial cytoplas-
mic LL-37 (n = 526), the majority displayed weak
intensity expression (n = 332/526, 63%).
Loss of LL-37 expression intensity is associated
with CRC progression
The expression intensity of LL-37 significantly
decreased with increasing UICC stage (p = 0.048)
(Figure 2B and Table 2). Specifically, our data
reveal that the switch in expression occurs at the
early stages of colonic carcinogenesis. Expression of
LL-37 was significantly lower in UICC stage 1
(p = 0.009), UICC stage 2 (p < 0.001), and UICC
stage 3 (p < 0.001) tumours compared to normal.
There was a significant reduction in LL-37 intensity in
UICC stage 2 (p = 0.019) and UICC stage 3
(p = 0.030) compared to UICC stage 1 tumours. There
was no difference in LL-37 expression intensity
between UICC stage 2 and UICC stage 3 tumours
(p = 0.706).
The expression of LL-37 in adjacent non-neoplastic
epithelium differs with tumour stage
There was a significant difference in epithelial LL-37
expression intensity between non-neoplastic normal
colonic mucosa from patients with UICC stage
1, UICC stage 2, and UICC stage 3 CRC (p = 0.001)
(Figure 2C and Table 2).
Epithelial LL-37 expression is not associated
with survival in CRC
Next, we assessed the expression of LL-37 in asso-
ciation with clinical and pathological parameters.
The epithelial expression of LL-37 was not associ-
ated with survival across the whole tissue cohort in
univariate analysis (Table 3 and supplementary
material, Figure S1A). Subgroup analysis of the dif-
ferent clinical and pathological features in isolation,
such as tumour stage (UICC stage 1–3), did not
reveal association with survival and LL-37 expres-
sion (data not included). Multivariate analysis did
not identify any association when factors such as
age or sex were accounted for (see supplementary
material, Figure S1B).
Epithelial LL-37 expression is associated with
tumour site but no other clinical or pathological
characteristics of CRC
Negative versus positive LL-37 expression was associ-
ated with tumour site (p = 0.028); positive expression
was especially associated with the proximal colon.
Otherwise, we did not identify a significant association
Table 2. Association between LL-37 expression intensity and histological diagnosis.















χ2 p χ2 p χ2 p χ2 p
Normal versus CRC 30.191 <0.001 – 0.016 25.153 <0.001 25.298 <0.001
Normal versus UICC stage 1 11.679 0.009 – 0.064 7.845 0.005 7.455 0.010
Normal versus UICC stage 2 36.916 <0.001 – 0.012 26.071 <0.001 27.158 <0.001
Normal versus UICC stage 3 32.600 <0.001 – 0.019 26.985 <0.001 21.108 <0.001
UICC stage 1 versus 2 versus 3 12.727 0.048 1.690 0.430 10.639 0.005 5.879 0.053
UICC stage 1 versus UICC stage 2 10.007 0.019 1.671 0.196 8.323 0.004 5.698 0.017
UICC stage 2 versus UICC stage 3 1.414 0.706 0.364 0.566 0.004 1.000 0.712 0.399
UICC stage 1 versus UICC stage 3 8.967 0.030 0.713 0.398 9.910 0.003 2.853 0.091
UICC stage 1 versus UICC stages 2 and 3 11.403 0.010 1.305 0.253 10.635 0.001 5.254 0.022
UICC stages 1 and 2 versus UICC stage 3 2.504 0.475 0.007 0.933 2.035 0.154 0.059 0.808
Normal from UICC stage 1 versus normal from UICC stage 2
versus normal from UICC stage 3
16.930 0.001 – – 5.301 0.090 16.931 <0.001
Analysed by chi-square tests. Values in bold indicate p < 0.05.
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with any additional clinical or pathological factors
(Table 3).
Density of T cell infiltrate is associated
with survival in CRC
As expected, survival across the tissue microarray was
associated with T cell infiltrate (see supplementary
material, Figure S2). The relationship between the
density of T cell infiltrate (CD3+, CD4+, and CD8+
cells) and overall survival validates the tissue microar-
ray as representative of pathology [18]. Representative
photomicrographs of T cell infiltrate are published pre-
viously [18].
Density of CD8+, but not CD3+ or CD4+, T cell
infiltrate is associated with LL-37 expression
intensity
The density of CD8+ T cell infiltrate was associated
with LL-37 expression across the microarray
(Table 4), and particularly absence versus presence of
CD8+ cells with increasing expression intensity of
LL-37 (p = 0.002). This association was not seen for
CD3+ or CD4+ cells (Table 4). To understand this
Table 4. Association between epithelial cell LL-37 expression intensity (absent, weak, moderate, or strong) and density of T cell infiltrate.












χ2 p χ2 p χ2 p χ2 p
CD3+ T cells
0 versus 1 versus 2 versus 3 6.294 0.710 1.435 0.697 1.545 0.672 2.718 0.437
0 and 1 versus 2 and 3 3.603 0.308 0.820 0.365 0.034 0.853 2.238 0.135
0 versus 1, 2, and 3 1.346 0.718 0.001 0.972 0.663 0.415 0.082 0.775
3 versus 0, 1, and 2 2.152 0.542 0.717 0.397 0.097 0.755 0.783 0.376
CD4+ T cells
0 versus 1 versus 2 versus 3 8.709 0.465 3.912 0.271 2.049 0.562 2.237 0.525
0 and 1 versus 2 and 3 5.321 0.150 3.024 0.082 0.127 0.721 1.337 0.248
0 versus 1, 2, and 3 2.294 0.514 0.463 0.496 1.760 0.185 0.006 0.937
3 versus 0, 1, and 2 0.755 0.860 0.097 0.755 0.019 0.890 0.414 0.520
CD8+ T cells
0 versus 1 versus 2 versus 3 17.083 0.047 8.051 0.045 0.011 1.000 6.704 0.082
0 and 1 versus 2 and 3 10.934 0.012 5.349 0.021 0.004 0.950 4.110 0.043
0 versus 1, 2, and 3 14.908 0.002 7.069 0.008 0.011 0.915 5.829 0.016
3 versus 0, 1, and 2 4.480 0.214 1.177 0.278 0.001 0.970 2.542 0.111
Analysed using categorical T cell infiltrate data (quartiles expressed as % of total immune cell density; 0 = 0–25%, 1 = 26–50%, 2 = 51–75%, and 3 = 76–100%)
with chi-square tests. Values in bold indicate p < 0.05.
Table 3. Association between LL-37 expression intensity and clinico-pathological characteristics.













χ2 p χ2 p χ2 p χ2 p
Gender 2.393 0.495 0.811 0.368 1.200 0.273 0.051 0.821
Age 6.250 0.100 0.034 0.853 2.642 0.104 0.723 0.395
Screen detected 2.986 0.392 – 0.459 0.141 0.747 – 0.211
Tumour site 9.709 0.137 7.132 0.028 0.080 0.961 2.196 0.334
Colon versus rectum 4.695 0.196 3.536 0.060 0.010 1.000 0.869 0.351
Tumour differentiation 2.471 0.479 – 0.565 2.042 0.153 – 0.388
Extra-mural venous invasion 3.065 0.383 1.139 0.286 0.683 0.409 0.097 0.755
Mismatch repair protein status 2.411 0.492 0.181 0.671 0.026 0.871 1.500 0.221
pT stage 15.137 0.087 2.521 0.471 7.005 0.072 8.824 0.032
pN stage 8.217 0.223 0.860 0.651 5.244 0.073 2.371 0.306
UICC stage 12.727 0.048 1.690 0.430 10.639 0.005 5.879 0.053
Survival 3.606 0.307 0.796 0.372 0.862 0.353 0.834 0.361
Parameters were analysed by chi-square tests and survival was analysed by Kaplan–Meier (log-rank) test. Values in bold indicate p < 0.05.
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relationship further, an analysis using continuous data
of the number of infiltrating CD8+ immune cells rev-
ealed that LL-37 expression is associated with the
number of CD8+ T cells in CRC (p = 0.003) (see sup-
plementary material, Figure S3): absent (215.43), weak
(275.45), moderate (285.33), and strong (220.98) mean
ranks suggest increased CD8+ cell infiltration from
absent through moderate LL-37 expression intensity
and then reduced CD8+ cell infiltration with strong
LL-37 expression. We next assessed the continuous
data of number of CD8+ cells in association with LL-
37 expression and other tumour characteristics. The
relationship between LL-37 expression and CD8+ T
cells was observed in colonic tumour site (p = 0.012),
moderate-to-well differentiation (p ≤ 0.005), absence
of EMVI (p ≤ 0.038), and UICC stage 3 tumour stage
(p ≤ 0.022) (see supplementary material, Table S1A–
F). Notably, the association between CD8+ cell infil-
trate and LL-37 expression was more pronounced
according to mismatch repair protein status, particu-
larly in mismatch repair proficient tumours (p ≤ 0.036)
(see supplementary material, Table S1F).
LL-37 does not impact expression of epithelial
barrier permeability or epithelial-derived cytokine
genes in a human colon-derived organoid model
We next turned our attention to the functional conse-
quences of LL-37 on the colonic epithelial barrier.
This was assessed using a human colon-derived
organoid culture with focus on the gene expression
profile of key genes in the regulation of permeability
and cytokine secretory capacity. The human colonic
organoids did not express IL-10, IL-22, or IL-27. Stim-
ulation with LL-37 did not significantly impact the
expression of key barrier permeability or epithelial-
derived cytokine genes (Figure 3).
Discussion
Cathelicidin exerts pleotropic effects depending on the
tissue type [2,3], and changes in expression are associ-
ated with cancer across different body sites [2]. Data
on the expression profile of cathelicidin in human
CRC are limited [13], and its biological impact in this
pathology is unknown. We previously reported that
loss of cathelicidin expression was associated with
CRC in a pre-clinical mouse model [5]. Here, we con-
firm translation of this pre-clinical data to human dis-
ease and show that loss of LL-37 expression is
associated with human CRC in a large, robust, well-
characterised tissue cohort of human CRCs that is rep-
resentative of this malignancy. This may indicate a
tumour suppressor role of LL-37 in CRC. This switch
to reduced expression in the cytoplasm of epithelial
cells occurs very early in the cancer process, with a
significant reduction between non-neoplastic mucosa
and the earliest stages of CRC. Given that the expres-
sion of LL-37 is not associated with survival,
expression intensity of LL-37 does not appear to be a
prognostic biomarker to aid clinical management
at the time of diagnosis. We did not assess whether
LL-37 expression is linked to treatment response in
our study.
Figure 3. Recombinant LL-37 stimulation of human colonic epithelial organoids does not impact expression of (A) key epithelial barrier
permeability genes or (B) epithelium-derived cytokine genes. Organoids did not express IL-10, IL-21, or IL-27.
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We next began to investigate how this dynamic LL-
37 expression profile impacts the biology of colorectal
carcinogenesis. Our previous data revealed that the
impact of cathelicidin in the gastrointestinal tract was
linked to the colonic microbiota [5]. Dysbiosis of the
microbiota is associated with CRC and there is evi-
dence that some bacterial species such as
Fusobacterium are enriched in CRC tissue [22–24]
due to an increase in bacterial translocation across the
epithelial barrier [25]. We hypothesised that LL-37
may impact regulatory elements of barrier integrity
and permeability, with loss of LL-37 expression asso-
ciated with increased permeability. In keeping with
this hypothesis, Tatsuta et al demonstrated that LL-
37-attenuated cigarette smoke induced epithelial
damage in the respiratory tract through effects on regu-
lation of epithelial permeability [26]. There are limited
data on the effect of LL-37 on the human gastrointesti-
nal epithelial barrier and previous mechanistic studies
used immortalised cell line models. Therefore, we
assessed the impact of LL-37 on permeability gene
expression in a human colon tissue-derived organoid
model. Organoids are complex, three-dimensional ex vivo
tissue cultures and represent a near-physiological model
with advantages over traditional two-dimensional immor-
talised cell cultures [27]. Permeability is regulated by an
interacting network of different families of proteins
located at the tight junction between epithelial cells, and
examples include the claudins, occludin, and tight junc-
tional proteins [28]. Here, we did not identify a change in
expression of key mediators regulating epithelial barrier
permeability and integrity in response to direct cat-
helicidin stimulation in our ex vivo human organoid
model. This is in keeping with our previous pre-clinical
in vivo assessment of intestinal permeability, where there
was no increase in serum FITC-dextran in cathelicidin
knockout mice and no change in expression of permeabil-
ity genes in the colonic mucosa [5]. However, the focus
of cathelicidin in the gut may be different depending on
the context. As an example, in our previous studies in
mouse models, knockout of the cathelicidin analogue
CRAMP was associated with shorter crypt length, and
this may indicate a role in epithelial cell proliferation in
normal homeostasis [5]. Other changes were identified,
such as changes in microbiota composition, and it is
unclear if the LL-37 effect on the epithelial barrier was
direct or indirect. In contrast, in the murine model of
CRC, loss of cathelicidin led to larger tumours suggesting
a tumour suppressor role, and this latter effect is mirrored
by our data here in a large cohort of human CRCs, and
the data by Ren et al [13] in previous related studies.
Therefore, the biological activities of cathelicidin in the
gut may be different depending on the context and we
need to consider this when interpreting the data from the
organoid models. Our organoid models were derived
from non-neoplastic mucosa and our data reveal novel
insights into cathelicidin biology in gut homeostasis, spe-
cifically on direct effects of LL-37 on epithelial cell func-
tion. It may be that the cathelicidin effect will be different
in organoid models derived from CRC and this requires
further attention to define the biology of cathelicidin in
the cancer context.
The immune response is one of the hallmarks of
cancer [29,30]. The tumour-infiltrating lymphocyte
phenotype is well established as a prognostic indicator
in colorectal malignancy [31] and is the basis of
the clinically applied immunoscore to aid with prog-
nostication [32]. The presence of CD8+ T cells is
associated with improved overall survival and cancer-
specific survival [33,34]. Here, in CRC, CD8+ cell
infiltrate is associated with increased intensity of epi-
thelial LL-37 expression from negative through weak
and moderate expression. However, this association is
less apparent in tumours that strongly express LL-37.
The reasons for this differential association and the
biological consequences of this are unknown. We can
speculate that the association may indicate a role of
LL-37 in microenvironmental changes that could
impact pathogenesis, and appears most relevant in
early colorectal neoplastic progression. It may be that
strong expression of LL-37 in the context of tumour
could reflect a change in the functional status of the
protein and this requires further investigation.
The relationship between LL-37 expression and
CD8+ T cell infiltrate was associated with mismatch
repair protein status. CD8 lymphocytes play a key role
in anti-tumoural response in the cancer microenviron-
ment, stimulating tumour cell apoptosis [35]. There is
a well-established link between mismatch repair pro-
tein status, immune cell infiltrate particularly CD8+
cells, expression of immune checkpoint inhibitors, and
immune escape of the tumour in CRC, and these fac-
tors have been the focus of investigation into the
predicted efficacy of immunotherapy in this subset of
CRCs [36]. The link between mismatch repair protein
status and CD8+ infiltrate is seen in other tumour
types such as pancreatic cancer [37]. Our study does
not explore whether LL-37 could impact the function of
CD8+ cells in CRC. However, this has been reported in
other studies across different pathologies. As an example,
LL-37 is overexpressed in skin in psoriasis where it acts
as an auto-antigen for CD8+ T cells, leading to the up-
regulation of markers of cytotoxic granule release, cyto-
kine release, and proliferation of these CD8+ cells, and
contributing to disease pathogenesis [38]. Findlay et al
[39] reported that LL-37-stimulated dendritic cells led to
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the proliferation, activation, and cytokine production by
CD8+ cells. Furthermore, tumour antigen-presenting LL-
37-stimulated dendritic cells led to increased migration
of activated CD8+ T cells into murine squamous cell car-
cinoma, resulting in tumour regression.
Overall, this study of a large robust cohort of
650 human CRC cases and a cutting-edge human gas-
trointestinal epithelial organoid model reveals novel
insights into the pathogenesis of CRC. We demon-
strate that there is dynamic expression of LL-37 in
human CRC and this is linked to CD8+ T cell infil-
trate, and that LL-37 does not impact expression of
human epithelial cell genes regulating permeability.
Further work is required to assess the biological conse-
quence of loss of LL-37 expression in CRC to uncover
novel treatment targets for this malignancy.
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Figure S1. Epithelial expression of LL-37 was not associated with survival in univariate or multivariate analysis
Figure S2. Densities of stromal CD3+, CD4+, and CD8+ T cells are associated with overall survival, which validates the TMA as representative
of pathology
Figure S3. Epithelial cytoplasmic LL-37 expression intensity is associated with density of stromal CD8+ T cells in CRC
Table S1. The association between epithelial cytoplasmic LL-37 expression intensity and density of T cell infiltrate when stratified by different
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